Drug rash with eosinophilia and systemic symptoms
| Drug rash with eosinophilia and systemic symptoms | |
|---|---|
| Other names | Drug induced hypersensitivity syndrome (DIHS), drug hypersensitivity syndrome (DHS), drug-induced delayed multiorgan hypersensitivity syndrome, drug-induced pseudolymphoma (formerly) |
| Specialty | Dermatology, Immunology |
| Symptoms | Rash, fever, sore throat, lymph node swelling, sores in mouth or other mucosal surfaces, facial swelling, itching |
| Complications | Kidney damage, liver damage, heart damage, lung damage |
| Usual onset | Usually 2-6 weeks after drug exposure |
| Causes | Medication exposure |
| Risk factors | Certain Human leukocyte antigen variants confer a greater risk after medication exposure |
| Diagnostic method | Clinical diagnosis. |
| Differential diagnosis | Stevens Johnson syndrome, Toxic epidermal necrolysis, Acute generalized exanthematous pustulosis |
| Treatment | Discontinuing the offending medication, supportive care, glucocorticoids, Anti IL-5 antibodies, immunosuppressants |
| Prognosis | Mortality rate varies, generally 1.2-7.1%, long term complications or disability is common |
| Frequency | Incidence 1 case per 1,000 people to 1 case per 10,000 people |
Drug rash with eosinophilia and systemic symptoms or drug reaction with eosinophilia and systemic symptoms (DRESS), also termed drug-induced hypersensitivity syndrome (DIHS), is a rare reaction to certain medications. It involves primarily a widespread skin rash, fever, swollen lymph nodes, and characteristic blood abnormalities such as an abnormally high level of eosinophils, low number of platelets, and increased number of atypical white blood cells (lymphocytes). DRESS usually involves damage to the internal organs via inflammation and the syndrome has about a 1.2-7% mortality rate. Treatment consists of stopping the offending medication and providing supportive care. Systemic corticosteroids are commonly used as well but no controlled clinical trials have assessed the efficacy of this treatment.
DRESS is classified as one form of severe cutaneous adverse reactions (SCARs). In addition to DRESS, SCARs includes four other drug-induced skin reactions: the Stevens–Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), Stevens–Johnson/toxic epidermal necrolysis overlap syndrome (SJS/TEN) and acute generalized exanthematous pustulosis (AGEP). The SCARs disorders have similar disease mechanisms. New strategies are in use or development to screen individuals at risk for DRESS to aid them in avoiding medications that increase the risk of DRESS. Alternative medications are used in all individuals testing positive for these predispositions.
Prior to 1996, there were numerous reports on individuals presenting with a medication-induced disorder now recognized as the DRESS syndrome. For example, anticonvulsants in the 1930s, phenytoin in 1950, and other medications in the ensuing years were reported to do so. The reports often named the disorder based on the medication evoking it, e.g. the anticonvulsant hypersensitivity syndrome, allopurinol hypersensitivity syndrome, and dapsone hypersensitivity syndrome. In 1996, however, the term DRESS syndrome was coined in a report attempting to simplify the terminology and consolidate these various clearly related syndromes into a single underlying disorder.
DRESS syndrome is thought to be a T-cell mediated immunologic reaction. The incidence is estimated to be 1 case per 1,000 people to 1 case per 10,000 people. Worldwide mortality varies between 1.2-7.1%, with the mortality in the United States being approximately 5%.